Wang 2017a.

Methods	Study design: Randomised clinical trial Study duration: January 2015 to December 2015 Duration of follow‐up: Not reported Setting: Hospital
Participants	Inclusion criteria: Diagnosed as HCC by pathology; expected survival > 3 months; Karnofsky score ≥ 70 Exclusion criteria: With cognitive disorder; with abnormal liver, renal, or cardiac function Age (mean ± SD, range): TACE + RFA: 53.42 ± 4.1 years, 39‐79 years; TACE alone: 53.25 ± 4.09 years, 44‐78 years Male (n/total): TACE + RFA: 28/42; TACE alone: 26/42
Interventions	TACE + RFA group (n = 42): TACE: Chemotherapeutic drugs: cisplatin 50 mg, epirubicin 30 mg, and mitomycin 10 mg RFA: Radio Therapeutics TMRF 2000 system TACE group (n = 42): Chemotherapeutic drugs: cisplatin 50 mg, epirubicin 30 mg, and mitomycin 10 mg
Outcomes	Serum level of ALT Serum level of AFP Tumour response, classified as complete response, partial response, stable disease, and progression Adverse events
Notes	Country of study: China Source of funding: None There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this.